MétaCan
Menu
Back to cohort

Abstract C246: SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma.

2013· article· en· W1992078544 on OpenAlexaff
Zhihua Li, Sina Haftchenary, Danielle Croucher, Patrick T. Gunning, Suzanne Trudel

Bibliographic record

VenueMolecular Cancer Therapeutics · 2013
Typearticle
Languageen
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsUniversity of TorontoPrincess Margaret Cancer Centre
Fundersnot available
KeywordsAnnexinSTAT3Viability assayAngiogenesisCancer researchMolecular biologyCell cultureAnnexin A5Multiple myelomaCancer cellChemistryApoptosisFlow cytometryBiologyMedicineCancerImmunologyBiochemistryInternal medicine

Abstract

fetched live from OpenAlex

Abstract Aberrant STAT3 signaling is prevalent in hematologic malignancies such as Multiple Myeloma (MM) and is recognized as a master regulator of tumor processes such as survival, angiogenesis, and drug resistance. Significant efforts have therefore focused on therapeutic targeting of STAT3 as an anti-cancer strategy. Based on rational structure-based design, we present pre-clinical findings for a newly developed small molecule STAT3 inhibitor, SH-4-54. SH-4-54 was designed to block the SH2 domain of STAT3 by mimicking its native phosphopeptide binding sequence and in turn prevent phosphorylation (activation) and disrupt transcriptionally active STAT3:STAT3 dimerization. SH-4-54 has been shown to have a KD for STAT3 protein of 300 nM by surface plasmon resonance and inhibits STAT3 SH2 domain-phosphopeptide interactions as assessed by a fluorescence polarization assay. The anti-MM activity of SH-4-54 was assessed using MTT assays against a panel of molecularly heterogeneous human myeloma cell lines (HMCLs), revealing potent and broad effects on cell viability with 10/15 HMCLs displaying IC50 values < 10 μM. Moreover, SH-4-54 induced apoptotic responses in HMCLs as evidenced by increased Annexin V staining. Promising results were observed for the effects of SH-4-54 on primary patient-derived myeloma cells. Using flow cytometric analysis of CD138 as a marker of myeloma cells and Annexin V staining, SH-4-54 was found to significantly reduce the percentage of CD138+/Annexin V negative, viable myeloma cells, while displaying little to no toxicity against the non-malignant (CD138−) cell fraction. Supporting the predicted molecular mechanisms of SH-4-54 activity, immunoblot analysis revealed that SH-4-54 inhibits constitutive STAT3 phosphorylation, but does not alter STAT3 protein levels. Furthermore, using HMCLs engineered to express a STAT3-driven luciferase reporter construct, SH-4-54 was found to significantly reduce STAT3 transcriptional activity, and consistently induce a reduction in proteins that encode STAT3 target genes such as c-Myc. Taken together, our results highlight the promising therapeutic potential of SH-4-54 and support the continued development of targeted therapies for MM with a focus on aberrant STAT signaling. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C246. Citation Format: Zhi Hua Li, Sina Haftchenary, Danielle Croucher, Patrick T. Gunning, Suzanne Trudel. SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C246.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.072
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.308
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicMonoclonal and Polyclonal Antibodies ResearchFrench-language works237,207